Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Duchenne Muscular Dystrophy Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.4% during the forecast period.
This report presents the market size and development trends by detailing the Duchenne Muscular Dystrophy Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Duchenne Muscular Dystrophy Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Duchenne Muscular Dystrophy Drugs industry and will help you to build a panoramic view of the industrial development.
Duchenne Muscular Dystrophy Drugs Market, By Type:
Exondys51
Translarna
Emflaza
Duchenne Muscular Dystrophy Drugs Market, By Application:
Hospitals
Home care settings
Clinics
Some of the leading players are as follows:
Nobelpharma
Asklepios BioPharmaceuticals
Marathon Pharmaceuticals
Pfizer
BioMarin Pharmaceutical
Summit Therapeutics
PTC Therapeutics
Bristol-Myers Squibb
Akashi Therapeutics
Janssen Pharmaceuticals
Acceleron Pharma
Sarepta Therapeutics
Eli Lilly
Santhera Pharmaceuticals
Taiho Pharmaceutical
Catabasis Pharmaceuticals
Nippon Shinyaku
Lexicon Pharmaceuticals
Capricor Therapeutics
Italfarmaco
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Duchenne Muscular Dystrophy Drugs Market: Technology Type Analysis
-
4.1 Duchenne Muscular Dystrophy Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Duchenne Muscular Dystrophy Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Exondys51
4.3.2 Translarna
4.3.3 Emflaza
5 Duchenne Muscular Dystrophy Drugs Market: Product Analysis
-
5.1 Duchenne Muscular Dystrophy Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Duchenne Muscular Dystrophy Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Duchenne Muscular Dystrophy Drugs Market: Application Analysis
-
6.1 Duchenne Muscular Dystrophy Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Duchenne Muscular Dystrophy Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospitals
6.3.2 Home care settings
6.3.3 Clinics
7 Duchenne Muscular Dystrophy Drugs Market: Regional Analysis
-
7.1 Duchenne Muscular Dystrophy Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Duchenne Muscular Dystrophy Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Nobelpharma
9.1.1 Nobelpharma Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Asklepios BioPharmaceuticals
9.2.1 Asklepios BioPharmaceuticals Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Marathon Pharmaceuticals
9.3.1 Marathon Pharmaceuticals Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Pfizer
9.4.1 Pfizer Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 BioMarin Pharmaceutical
9.5.1 BioMarin Pharmaceutical Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Summit Therapeutics
9.6.1 Summit Therapeutics Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 PTC Therapeutics
9.7.1 PTC Therapeutics Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Bristol-Myers Squibb
9.8.1 Bristol-Myers Squibb Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Akashi Therapeutics
9.9.1 Akashi Therapeutics Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Janssen Pharmaceuticals
9.10.1 Janssen Pharmaceuticals Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Acceleron Pharma
9.11.1 Acceleron Pharma Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Sarepta Therapeutics
9.12.1 Sarepta Therapeutics Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Eli Lilly
9.13.1 Eli Lilly Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Santhera Pharmaceuticals
9.14.1 Santhera Pharmaceuticals Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Taiho Pharmaceutical
9.15.1 Taiho Pharmaceutical Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Catabasis Pharmaceuticals
9.16.1 Catabasis Pharmaceuticals Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Nippon Shinyaku
9.17.1 Nippon Shinyaku Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
9.18 Lexicon Pharmaceuticals
9.18.1 Lexicon Pharmaceuticals Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis
9.19 Capricor Therapeutics
9.19.1 Capricor Therapeutics Company overview
9.19.2 Financial performance
9.19.3 Product benchmarking
9.19.4 Strategic initiatives
9.19.5 SWOT analysis
9.20 Italfarmaco
9.20.1 Italfarmaco Company overview
9.20.2 Financial performance
9.20.3 Product benchmarking
9.20.4 Strategic initiatives
9.20.5 SWOT analysis
The List of Tables and Figures (Totals 81 Figures and 128 Tables)
Figure Exondys51 Duchenne Muscular Dystrophy Drugs market, 2015 - 2026 (USD Million)
Figure Translarna Duchenne Muscular Dystrophy Drugs market, 2015 - 2026 (USD Million)
Figure Emflaza Duchenne Muscular Dystrophy Drugs market, 2015 - 2026 (USD Million)
Figure Hospitals market, 2015 - 2026 (USD Million)
Figure Home care settings market, 2015 - 2026 (USD Million)
Figure Clinics market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Duchenne Muscular Dystrophy Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Duchenne Muscular Dystrophy Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Duchenne Muscular Dystrophy Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Duchenne Muscular Dystrophy Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Duchenne Muscular Dystrophy Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Duchenne Muscular Dystrophy Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Duchenne Muscular Dystrophy Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Duchenne Muscular Dystrophy Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Nobelpharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Asklepios BioPharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Marathon Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table BioMarin Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Summit Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table PTC Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Akashi Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Janssen Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Acceleron Pharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sarepta Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Santhera Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Taiho Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Catabasis Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Nippon Shinyaku Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Lexicon Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Capricor Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Italfarmaco Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
